title: Mitral valve replacement with glutaraldehyde preserved aortic allografts.
abstract: OBJECTIVE
  To present long-term results after mitral valve replacement with stent mounted glutaraldehyde preserved aortic allografts in patients older than 15 years. The clinical support for this study was to combine the glutaraldehyde technique of biological tissue preservation with the advantages of allografts when compared to xenografts. This was demonstrated in previous studies using other methods of tissue processing.
  
  
  METHODS
  Between September 1984 and November 1994, 70 patients aged 16-77 years (mean 35.4 years) underwent mitral valve replacement with this preserved and mounted allograft. Of these, 40 patients (57.2%) were aged 16-35 years and 15 (21.4%) were 20 years old or younger; 46 (65.7%) were females and 24 (34.3%) males. Single mitral valve replacement was performed in 60 patients and 10 were also subjected to other combined cardiac procedures. Human aortic valves were obtained during routine autopsy, processed in glutaraldehyde and mounted into flexible stents, using the same technique as that used for porcine bioprostheses.
  
  
  RESULTS
  Hospital mortality was 1.4%. Total follow-up was 543.1 patient-years, corresponding to a mean follow-up of 7.9 years per patient. Echocardiography demonstrated a hemodynamic performance similar to porcine bioprostheses. Late mortality was 0.7 +/- 0.6% per patient-year and the causes were congestive heart failure in 2, prosthetic endocarditis in 1 and acute myocardial infarction in 1. The 12-year actuarial survival was 92.4 +/- 3.2%. The incidence of late complications was 5.2 +/- 1.2% per patient-year, including congestive heart failure, prosthetic endocarditis, periprosthetic leak, thromboembolic episodes, recurrence of rheumatic disease, coronary artery disease and allograft failure. Complications related to heart disease represented 2.8 +/- 0.6% and allobioprosthesis-related 2.4 +/- 0.5% per patient-year. The 12-year actuarial freedom from primary valve failure was 81.0 +/- 15.0%. The incidence of reoperations was 1.5 +/- 0.8% per patient-year and the main indication was prosthetic endocarditis. Other causes were periprosthetic leak, aortic insufficiency in the native aortic valve and allobioprosthesis dysfunction. Functional results demonstrated a significant improvement in patients clinical condition.
  
  
  CONCLUSIONS
  This 12-year follow-up shows a very low incidence of primary allograft failure for patients older than 15 years undergoing mitral valve replacement, and much superior than our results with porcine bioprosthesis in the same age group. This supports our assumption that this investigational valve represents a new advance in cardiac valve surgery.
authors.affiliation: Hospital Felicio Rocho, Federal University of Minas Gerais, Medical School, Belo Horizonte, Brazil. fsalles@gold.com.br
authors.forename: C A
authors.initials: CA
authors.lastname: Salles
authors.forename: E
authors.initials: E
authors.lastname: Buffolo
authors.forename: J C
authors.initials: JC
authors.lastname: Andrade
authors.forename: J H
authors.initials: JH
authors.lastname: Palma
authors.forename: R R
authors.initials: RR
authors.lastname: Silva
authors.forename: R
authors.initials: R
authors.lastname: Santiago
authors.forename: I S
authors.initials: IS
authors.lastname: Casagrande
authors.forename: M C
authors.initials: MC
authors.lastname: Moreira
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001021:Aortic Valve / Q000637:transplantation*; D001705:Bioprosthesis; D004696:Endocarditis / Q000209:etiology; D005260:Female; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve; D011183:Postoperative Complications / Q000401:mortality; D016459:Prosthesis-Related Infections; D012086:Reoperation; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome